GSK and Merck Group-backed Progyny floated in an offering that involved the fertility benefits manager pricing its shares below their range.

SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.

Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.

Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.